“[Clinical and economic evaluation of the introduction of the combinazion trametinib + dabrafenib in the management of advanced melanoma in the Italian market]”, FE, vol. 17, no. 3S, pp. 1–32, Dec. 2016, doi: 10.7175/fe.v17i3S.1279.